Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three widely used inhalation modes: nebulizer, DPI and pMDI Initiation of multiple dose part of pMDI trial postponed due to the
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP ticker.
The condition causes loss of lung function, hospitalisations and death. COPD affects approximately 384 million people worldwide. It is projected to be the third leading cause of death by 2030, according to the World Health Organization.Find out more
31 March 2020